Summary & Overview
HCPCS Q9970: Ferric Carboxymaltose Injection, 1mg
HCPCS Level II code Q9970 designates the administration of ferric carboxymaltose measured per milligram, used for intravenous iron therapy in patients with iron deficiency or related conditions requiring parenteral iron. Nationally, this code matters because accurate coding of iron infusions affects clinical documentation, billing precision, and aggregate utilization reporting for costly biologic and infused products. It also supports appropriate tracking of drug dosing when billed per milligram.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The summary addresses payer coverage considerations and how coding practice can influence reimbursement and utilization measurements across commercial and federal programs.
Readers will learn the clinical context for use of ferric carboxymaltose, the typical sites where the service is delivered, and the types of benchmarks and policy updates that affect billing for infused iron products. The publication also outlines expected data elements available in claims (drug dose, administration route, site of service) and notes where input data is not available. This resource is intended to clarify coding nomenclature and provide a foundation for further operational or policy analysis of intravenous iron administration.
Billing Code Overview
HCPCS Level II code Q9970 represents injection, ferric carboxymaltose, 1mg. This code denotes administration of an intravenous iron preparation, ferric carboxymaltose, measured per milligram.
-
Service type: Intravenous iron infusion/injection
-
Typical site of service: Hospital outpatient infusion center, clinic infusion suite, or other outpatient facility
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with iron-deficiency anemia who has not adequately responded to or cannot tolerate oral iron therapy. The patient presents to an outpatient infusion center, primary care clinic with infusion capability, or hospital outpatient department for intravenous iron replacement. Ferric carboxymaltose is administered as a slow IV push or infusion dosed by total iron deficit; Q9970 represents billing in 1 mg increments of ferric carboxymaltose. The clinical workflow includes verification of the indication and recent hemoglobin/iron studies, informed consent documented, baseline vitals and allergy assessment, IV access placement, administration of the calculated dose of ferric carboxymaltose with monitoring for infusion reactions during and for a brief observation period after administration, documentation of lot number and amount administered, and scheduling of follow-up laboratory testing and clinical reassessment. Typical sites of service are outpatient infusion centers, ambulatory care clinics with infusion capability, and hospital outpatient departments. Relevant clinical staff include an ordering provider (e.g., hematologist, family physician), registered nurse or infusion nurse to administer the injection, and pharmacist or medication safety officer to verify dosing and prepare the product.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, Separately Identifiable Evaluation and Management Service by the Same Physician on the Day of a Procedure |